Hikma Pharmaceuticals PLC (HIK.L)
GBp 1886.0
(0.91%)
GBp 1886.0
(0.91%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | 608 Million | 530 Million | 638 Million | 464 Million | 472 Million | 430 Million |
| Net Income | 190 Million | 188 Million | 421 Million | 431 Million | 486 Million | 282 Million |
| Depreciation & Amortization | 190 Million | 182 Million | 169 Million | 125 Million | 107 Million | 99 Million |
| Deferred income taxes | - | 76 Million | 99 Million | 200 Million | -20 Million | 71 Million |
| Stock-based compensation | 25 Million | 22 Million | 29 Million | 27 Million | 24 Million | 21 Million |
| Change in working capital | -8 Million | -98 Million | -128 Million | -227 Million | -4 Million | -92 Million |
| Other non-cash items | 211 Million | 160 Million | 48 Million | -92 Million | -121 Million | 49 Million |
| Investing Cash Flow | -333 Million | -607 Million | -238 Million | -283 Million | -151 Million | -96 Million |
| Investments in PPE | -169 Million | -138 Million | -145 Million | -172 Million | -119 Million | -107 Million |
| Acquisitions | -98 Million | -380 Million | -17 Million | -60 Million | 19 Million | 27 Million |
| Investment purchases | -27 Million | -15 Million | -3 Million | -5 Million | -6 Million | -4 Million |
| Sales/Maturities of investments | 1 Million | 395 Million | 6 Million | 2 Million | 14 Million | 4 Million |
| Other Investing Activities | -66 Million | -469 Million | -79 Million | -48 Million | -59 Million | -16 Million |
| Financing Cash Flow | -337 Million | -58 Million | -287 Million | -298 Million | -155 Million | -278 Million |
| Debt repayment | -73 Million | -971 Million | -76 Million | -1.38 Billion | -23 Million | -224 Million |
| Dividends payments | -137 Million | -125 Million | -120 Million | -109 Million | -97 Million | -84 Million |
| Common Stock Repurchased | - | -300 Million | - | -375 Million | - | - |
| Common Stock Issuance | - | 1.27 Billion | - | 1.76 Billion | - | - |
| Other Financing Activities | -127 Million | 67 Million | -91 Million | -189 Million | -35 Million | 30 Million |
| Accounts receivables | -24 Million | 4 Million | -166 Million | -47 Million | 21 Million | -41 Million |
| Accounts payables | - | 49 Million | -86 Million | -13 Million | 34 Million | - |
| Inventory | -115 Million | -102 Million | 38 Million | -180 Million | -25 Million | -51 Million |
| Other working capital | 131 Million | -49 Million | 86 Million | 13 Million | -34 Million | -21 Million |
| Cash at beginning of period | 270 Million | 426 Million | 323 Million | 442 Million | 276 Million | 227 Million |
| Cash at end of period | 205 Million | 270 Million | 426 Million | 323 Million | 442 Million | 276 Million |
| Capital Expenditure | -169 Million | -138 Million | -145 Million | -172 Million | -119 Million | -107 Million |
| Effect of forex changes on cash | -3 Million | -21 Million | -10 Million | -2 Million | - | -7 Million |
| Net cash flow / Change in cash | -65 Million | -156 Million | 103 Million | -119 Million | 166 Million | 49 Million |
| Free Cash Flow | 439 Million | 392 Million | 493 Million | 292 Million | 353 Million | 323 Million |
| Breakdown | 2024 Q2 | 2023 Q4 | 2023 FY | 2023 Q2 | 2022 FY | 2022 Q4 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | 226 Million | 59 Million | 190 Million | 131 Million | 188 Million | 15 Million |
| Depreciation & Amortization | 102 Million | 48 Million | 190 Million | 142 Million | 182 Million | 90 Million |
| Deferred income taxes | - | - | - | - | 76 Million | 1 Million |
| Stock-based compensation | 15 Million | 15 Million | 25 Million | 10 Million | 22 Million | 12 Million |
| Change in working capital | -223 Million | 139 Million | -8 Million | -147 Million | -98 Million | -21 Million |
| Other non-cash items | 78 Million | 125 Million | 211 Million | 86 Million | 160 Million | 265 Million |
| Investing Cash Flow | -106 Million | -214 Million | -333 Million | -119 Million | -607 Million | -101 Million |
| Investments in PPE | -69 Million | -85 Million | -169 Million | -84 Million | -138 Million | -75 Million |
| Acquisitions | - | -88 Million | -98 Million | -10 Million | -380 Million | - |
| Investment purchases | - | - | -27 Million | - | -15 Million | - |
| Sales/Maturities of investments | - | - | 1 Million | - | 395 Million | - |
| Other Investing Activities | -37 Million | -41 Million | -66 Million | -25 Million | -469 Million | -26 Million |
| Financing Cash Flow | -52 Million | -239 Million | -337 Million | -98 Million | -58 Million | -349 Million |
| Debt repayment | -47 Million | - | -73 Million | -14 Million | -971 Million | - |
| Dividends payments | -104 Million | -55 Million | -137 Million | -82 Million | -125 Million | -42 Million |
| Common Stock Repurchased | - | - | - | - | -300 Million | - |
| Common Stock Issuance | - | - | - | - | 1.27 Billion | - |
| Other Financing Activities | 5 Million | -184 Million | -127 Million | -2 Million | 67 Million | -307 Million |
| Accounts receivables | -130 Million | 51 Million | -24 Million | -75 Million | 4 Million | 11 Million |
| Accounts payables | - | - | - | - | 49 Million | - |
| Inventory | -66 Million | -29 Million | -115 Million | -86 Million | -102 Million | -24 Million |
| Other working capital | -27 Million | 117 Million | 131 Million | 14 Million | -49 Million | -8 Million |
| Cash at beginning of period | 205 Million | 272 Million | 270 Million | 270 Million | 426 Million | 371 Million |
| Cash at end of period | 236 Million | 205 Million | 205 Million | 272 Million | 270 Million | 270 Million |
| Capital Expenditure | -69 Million | -85 Million | -169 Million | -84 Million | -138 Million | -75 Million |
| Effect of forex changes on cash | -9 Million | - | -3 Million | -3 Million | -21 Million | -12 Million |
| Net cash flow / Change in cash | 31 Million | -67 Million | -65 Million | 2 Million | -156 Million | -101 Million |
| Free Cash Flow | 129 Million | 301 Million | 439 Million | 138 Million | 392 Million | 286 Million |
300115
GLASF
9562
NIOIF
MCT
TGL